Scientists at the CSIR-Centre for Cellular and Molecular Biology identified two small molecules that stop Candida albicans from shifting into its infection-associated filamentous form without halting its growth, The Times of India reported.
In Plain English: The Clinical Takeaway
- Targeting Shape, Not Life: The newly identified compounds prevent the fungus from changing its structure—blocking a key step that makes infections severe—while allowing the organism to continue normal cellular growth.
- Enhancing Existing Medications: Laboratory tests showed that one of the lead compounds reduced biofilm layers and made the fungus significantly more susceptible to standard antifungal treatments like fluconazole and amphotericin B.
- Early Laboratory Stage: These findings are strictly preclinical, meaning the compounds are research candidates that require extensive safety and efficacy testing before any human trials can be considered.
Targeting Fungal Morphogenesis and Glycolysis
Candida albicans exists naturally on human skin, but it can trigger dangerous systemic infections upon entering the bloodstream or internal organs. The transition from rounded yeast cells to long filaments makes the pathogen much harder for the human immune system to control. Earlier research from Dr Sriram Varahan’s laboratory pointed to glycolysis—the metabolic pathway cells use to process sugar—as the primary switch controlling this structural transformation.
The research team screened a library of small molecules that target this metabolic pathway. They found two specific compounds that successfully inhibited filament formation while letting the fungus grow solely as rounded cells. The work also isolated pyruvate kinase, an enzyme active in glycolysis, as a key target for regulating fungal morphogenesis.
| Research Component | Observed Effect | Therapeutic Implication |
|---|---|---|
| Glycolysis Targeting | Inhibited filament formation in Candida albicans | Prevents transition to the invasive form without killing the microbe |
| Lead Compound Testing | Reduced biofilm formation in laboratory settings | Removes protective shields that block standard antifungal drugs |
| Combination Exposure | Increased susceptibility to fluconazole and amphotericin B | Supports and reinforces existing clinical treatment options |
Preclinical Survival and Treatment Resistance
Microbial drug resistance remains a major public health concern as fungal pathogens become more common and therapeutic choices stay limited. One of the tested compounds successfully lowered biofilm production during laboratory experiments. Biofilms act as protective shields that protect the fungus from conventional antifungal therapies. By breaking down these barriers, the compound increased fungal sensitivity to standard treatments like fluconazole and amphotericin B.
Furthermore, a lead compound significantly improved survival rates in mice suffering from systemic Candida infections. Researchers published these findings in ACS Infectious Diseases, pointing toward a brand-new strategy that complements existing drugs rather than relying solely on agents designed to kill the pathogen outright.
“Our findings suggest that fungal disease-associated behaviour can be targeted without necessarily stopping fungal growth,” said Dhrumi Shah, the study’s first author.
Varahan said that further research must clarify the exact mechanisms of these compounds, optimize their molecular properties, and evaluate their overall suitability for drug development. The experiments conducted in mice remain preclinical and do not prove effectiveness in humans.
The CSIR-Centre for Cellular and Molecular Biology was set up initially as a semi-autonomous centre on 1 April 1977, with its nucleus formed by the Biochemistry Division of the Regional Research Laboratory in Hyderabad. During 1981–82, it was accorded the status of a full-fledged national laboratory with its own Executive Committee and Scientific Advisory Council.
Designated as a “Centre of Excellence” by the Global Molecular and Cell Biology Network, UNESCO, the institution includes an annexe known as the Laboratory for the Conservation of Endangered Species, which uses modern biological techniques and assisted reproductive technologies to conserve Indian wildlife and curb wildlife crime.
“The study does not establish these compounds as approved antifungal drugs; rather, it identifies promising candidates and a potential strategy for further development,” Varahan told The Times of India.